Loading...
Docoh

Durect (DRRX)

DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program. DUR-928, the company's lead drug candidate is in clinical development for the potential treatment of alcohol-associated hepatitis (AH) for which FDA has granted a Fast Track Designation, COVID-19 patients with acute liver or kidney injury, and non-alcoholic steatohepatitis (NASH). DURECT's proprietary drug delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs. One late-stage product candidate in this category is POSIMIR® (bupivacaine sustained-release solution), an investigational locally-acting, non-opioid analgesic intended to provide up to three days of continuous pain relief after surgery.

DRRX stock data

Calendar

5 Aug 22
28 Sep 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 47.29M 47.29M 47.29M 47.29M 47.29M 47.29M
Cash burn (monthly) 768.33K 744.83K 3.7M 3.12M 3.36M 2.84M
Cash used (since last report) 2.27M 2.2M 10.91M 9.21M 9.92M 8.39M
Cash remaining 45.02M 45.09M 36.37M 38.08M 37.36M 38.89M
Runway (months of cash) 58.6 60.5 9.8 12.2 11.1 13.7

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
19 Aug 22 Robertson Judith J. Common Stock Buy Acquire P No No 0.85 9,411.764 8K 356,131.764
18 Aug 22 Robertson Judith J. Common Stock Buy Acquire P No No 0.8499 71,531 60.79K 346,720
17 Aug 22 Robertson Judith J. Common Stock Buy Acquire P No No 0.8494 8,130 6.91K 275,189
17 Aug 22 Robertson Judith J. Common Stock Buy Acquire P No No 0.83 2,059 1.71K 267,059
12 Aug 22 Gail J Maderis Common Stock Buy Acquire P Yes No 0.7139 25,204 17.99K 200,000
11 Aug 22 Gail J Maderis Common Stock Buy Acquire P Yes No 0.6986 24,796 17.32K 174,796
10 Aug 22 Gail J Maderis Common Stock Buy Acquire P Yes No 0.6859 79,693 54.66K 150,000
9 Aug 22 Gail J Maderis Common Stock Buy Acquire P Yes No 0.6423 70,307 45.16K 70,307
42.8% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 88 97 -9.3%
Opened positions 18 11 +63.6%
Closed positions 27 15 +80.0%
Increased positions 21 17 +23.5%
Reduced positions 24 33 -27.3%
13F shares Current Prev Q Change
Total value 99.33M 77.14M +28.8%
Total shares 97.39M 115.14M -15.4%
Total puts 0 0
Total calls 453.6K 301.3K +50.5%
Total put/call ratio
Largest owners Shares Value Change
Bleichroeder 26.41M $12.63M 0.0%
Lion Point Capital 13.03M $6.25M -15.9%
Vanguard 10.02M $4.79M -11.2%
Ingalls & Snyder 9.06M $4.33M +25.1%
Antara Capital 4.66M $2.23M +1.9%
Millennium Management 4.42M $2.11M +2022.8%
CM Management 3.75M $1.79M +6.1%
Renaissance Technologies 3.34M $1.6M -4.5%
Beirne Wealth Consulting Services 3.07M $1.47M +11.3%
BLK Blackrock 2.93M $1.4M -78.8%
Largest transactions Shares Bought/sold Change
BLK Blackrock 2.93M -10.86M -78.8%
Millennium Management 4.42M +4.21M +2022.8%
STT State Street 770.58K -3.21M -80.6%
JPM JPMorgan Chase & Co. 1.09K -2.74M -100.0%
Lion Point Capital 13.03M -2.46M -15.9%
Ingalls & Snyder 9.06M +1.82M +25.1%
Geode Capital Management 2.03M -1.78M -46.8%
NTRS Northern Trust 405.74K -1.58M -79.6%
Vanguard 10.02M -1.27M -11.2%
Ergoteles 1M +1M NEW

Financial report summary

?
Management Discussion
  • We recognize revenues from collaborative research and development activities and service contracts. Collaborative research and development and other revenue primarily represents reimbursement
  • of qualified expenses related to collaborative agreements with various third parties to research, develop and commercialize potential products using our drug delivery technologies, and revenue from the recognition of upfront fees and milestone payments in connection with our collaborative or license agreements.
  • We expect our collaborative research and development and other revenues to fluctuate in future periods pending our efforts to enter into potential new collaborations, our existing third-party collaborators’ commitment to and progress in the research and development programs, and any royalty or earn-out revenue recognized from collaborators or counterparties. The collaborative research and development and other revenues associated with our major collaborators or counterparties are as follows (in thousands):

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: back, began, blinding, clarity, Experimental, Lam, Liangpunsakul, Lin, PDUFA, reauthorization, refinance, regeneration, slightly, user, wage
Removed: AASLD, attracting, binding, CLOUDTM, consummate, consummation, corticosteroid, defer, DSMB, entry, exploitation, explored, forgo, hire, impacting, IND, intensive, PPE, proven, reclassified, recovered, saving, SOC, tolerable, unit